市場調査レポート

商品コード

1677918

人獣共通感染症治療市場規模、シェア、成長分析：疾患タイプ別、治療タイプ別、投与経路別、エンドユーザー別、地域別 - 産業予測 2025～2032年

Zoonotic Disease Treatment Market Size, Share, and Growth Analysis, By Disease Type (Rabies, Lyme Disease), By Treatment Type (Vaccines, Antiviral Drugs), By Administration Route, By End User, By Region - Industry Forecast 2025-2032

出版日: 2025年03月05日
発行: SkyQuest
ページ情報: 英文 219 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 763,518円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 893,172円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,022,826円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=144.06円

全表示
概要
目次

概要

サンプル依頼リストに入れる

人獣共通感染症治療の市場規模は2023年に416億5,000万米ドルで、2024年の442億3,000万米ドルから2032年には715億7,000万米ドルに成長し、予測期間中（2025～2032年）のCAGRは6.2％で成長する見通しです。

疾病管理予防センターによると、動物から人間に感染する人獣共通感染症は、毎年数万人のアメリカ人を苦しめると予測されています。急速な都市化と人口増加は、特に衛生状態の悪い地域において、こうした問題を悪化させる可能性が高いです。さらに、動物性タンパク質と脂肪の需要の増加が、人獣共通感染症治療市場を牽引すると予想されます。ペット飼育の普及は交友関係をもたらすが、同時に疾病トランスミッションのリスクももたらします。しかし、新興諸国における認知度の低さや研究コストの高さといった障壁が、市場成長の妨げになる可能性があります。とはいえ、今後数年間は、動物の健康ニーズに合わせた革新的な治療法の開発により、世界市場の拡大が見込まれます。

北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州地域
アジア太平洋地域
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
中東・アフリカ
- GCC諸国
- 南アフリカ
- その他中東・アフリカ

競合情報

上位5社の比較
主要企業の市場ポジショニング（2024年）
主な市場企業が採用した戦略
最近の市場動向
企業の市場シェア分析（2024年）
主要企業の企業プロファイル
- 企業の詳細
- 製品ポートフォリオ分析
- 企業のセグメント別シェア分析
- 収益の前年比比較（2022-2024）

主要企業プロファイル

GlaxoSmithKline plc（UK）
Pfizer Inc.（USA）
Merck & Co., Inc.（USA）
Novartis AG（Switzerland）
Johnson & Johnson（USA）
F. Hoffmann-La Roche AG（Switzerland）
AstraZeneca plc（UK）
Bayer AG（Germany）
Eli Lilly and Company（USA）
AbbVie Inc.（USA）
Gilead Sciences, Inc.（USA）
Bristol-Myers Squibb Company（USA）
Takeda Pharmaceutical Company Limited（Japan）
Boehringer Ingelheim GmbH（Germany）
BioNTech SE（Germany）
Moderna, Inc.（USA）
Inovio Pharmaceuticals, Inc.（USA）
Emergent BioSolutions Inc.（USA）

結論と提言

Product Code: SQMIG35I2117

Zoonotic Disease Treatment Market size was valued at USD 41.65 billion in 2023 and is poised to grow from USD 44.23 billion in 2024 to USD 71.57 billion by 2032, growing at a CAGR of 6.2% during the forecast period (2025-2032).

According to the Centers for Disease Control and Prevention, zoonotic diseases, transmitted from animals to humans, are projected to afflict tens of thousands of Americans annually. Rapid urbanization and population growth are likely to exacerbate these issues, especially in areas with poor sanitation. Additionally, the increasing demand for animal proteins and fats is expected to drive the market for zoonotic disease treatments. The prevalence of pet ownership provides companionship but also introduces the risk of disease transmission. However, barriers such as limited awareness in developing countries and high research costs could hinder market growth. Nonetheless, the global market is poised for expansion with the development of innovative therapies tailored to animal health needs in the coming years.

Top-down and bottom-up approaches were used to estimate and validate the size of the Zoonotic Disease Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Zoonotic Disease Treatment Market Segments Analysis

Global Zoonotic Disease Treatment Market is segmented by Disease Type, Treatment Type, Administration Route, End User and region. Based on Disease Type, the market is segmented into Rabies, Lyme Disease, Zika Virus, West Nile Virus, Hantavirus, Malaria, Tuberculosis, Relapsing Fever, Viral Hepatitis and Others. Based on Treatment Type, the market is segmented into Vaccines, Antiviral Drugs, Antibiotics, Immunoglobulins, Antibacterial Medication, Antifungal Medication and Others. Based on Administration Route, the market is segmented into Intravenous, Intramuscular and Oral. Based on End User, the market is segmented into Hospitals, Ambulatory Surgical Centers, Homecare Settings, Research Institutions and Clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Zoonotic Disease Treatment Market

The zoonotic disease treatment market is being propelled by a multitude of factors, including the surging occurrence of zoonotic diseases and a growing awareness of their transmission. Additionally, the continuous development of innovative and effective treatments, alongside supportive government initiatives, plays a significant role in market growth. Furthermore, technological advancements and a rise in investments directed toward research and development further contribute to the expansion of this market. Collectively, these elements underscore the urgent need for effective treatment options and underscore the importance of addressing zoonotic diseases in public health strategies.

Restraints in the Zoonotic Disease Treatment Market

Despite the considerable growth potential of the zoonotic disease treatment market, several factors may impede its progress. The limited availability of effective treatments and the high costs associated with these therapies are significant barriers. Additionally, insufficient investment in research and development presents a further challenge. The market's growth may also be affected by the rise of generic medications and the impending patent expirations of established brands. Furthermore, a shortage of skilled professionals and inadequate healthcare infrastructure in developing countries complicate the situation. High capital requirements for research and development, coupled with a general lack of public awareness, further restrain market expansion.

Market Trends of the Zoonotic Disease Treatment Market

The Zoonotic Disease Treatment market is experiencing a significant upward trend, propelled by the rising incidence of zoonotic infections linked to urbanization, deforestation, and climate change. As ecosystems are disrupted, the interaction between humans and wildlife intensifies, facilitating the transmission of pathogens. This surge in disease awareness is prompting an urgent demand for innovative treatments and vaccines. Furthermore, increased government funding for research and development, alongside advancements in biotechnology, are catalyzing market expansion. With a growing focus on preventative measures and rapid response strategies, the Zoonotic Disease Treatment market is poised for robust growth in the coming years.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Case Studies

Global Zoonotic Disease Treatment Market Size by Disease Type & CAGR (2025-2032)

Market Overview
Rabies
Lyme Disease
Zika Virus
West Nile Virus
Hantavirus
Malaria
Tuberculosis
Relapsing Fever
Viral Hepatitis
Others

Global Zoonotic Disease Treatment Market Size by Treatment Type & CAGR (2025-2032)

Market Overview
Vaccines
Antiviral Drugs
Antibiotics
Immunoglobulins
Antibacterial Medication
Antifungal Medication
Others

Global Zoonotic Disease Treatment Market Size by Administration Route & CAGR (2025-2032)

Market Overview
Intravenous
Intramuscular
Oral

Global Zoonotic Disease Treatment Market Size by End User & CAGR (2025-2032)

Market Overview
Hospitals
Ambulatory Surgical Centers
Homecare Settings
Research Institutions
Clinics

Global Zoonotic Disease Treatment Market Size & CAGR (2025-2032)

North America (Disease Type, Treatment Type, Administration Route, End User)
- US
- Canada
Europe (Disease Type, Treatment Type, Administration Route, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Disease Type, Treatment Type, Administration Route, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Disease Type, Treatment Type, Administration Route, End User)
- Brazil
- Rest of Latin America
Middle East & Africa (Disease Type, Treatment Type, Administration Route, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

GlaxoSmithKline plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioNTech SE (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Moderna, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Inovio Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Emergent BioSolutions Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments

人獣共通感染症治療市場規模、シェア、成長分析：疾患タイプ別、治療タイプ別、投与経路別、エンドユーザー別、地域別 - 産業予測 2025～2032年

Zoonotic Disease Treatment Market Size, Share, and Growth Analysis, By Disease Type (Rabies, Lyme Disease), By Treatment Type (Vaccines, Antiviral Drugs), By Administration Route, By End User, By Region - Industry Forecast 2025-2032

目次

イントロダクション

調査手法

エグゼクティブサマリー

市場力学と見通し

主な市場の考察

人獣共通感染症治療市場規模：疾患タイプ別& CAGR（2025-2032）

人獣共通感染症治療市場規模：治療タイプ別& CAGR（2025-2032）

人獣共通感染症治療市場規模：投与経路別& CAGR（2025-2032）

人獣共通感染症治療市場規模：エンドユーザー別& CAGR（2025-2032）

人獣共通感染症治療市場規模：地域別& CAGR（2025-2032）